452. Invasive pneumoccocal diseases (IPD) in people without comorbidities
Session: Poster Abstract Session: Pneumococcal Vaccine in Children and Adults
Thursday, October 3, 2013
Room: The Moscone Center: Poster Hall C
  • NACINOVICH FRANCISCO - IPD in people without comorbidities - IDweek 2013.pdf (1.3 MB)
  • Background:


    IPD remains a major cause of morbidity and mortality worldwide and developing countries bear the major burden of this challenging disease. Occurs principally in the extremes of age (children <2 yo and adults >65 yo) and people with cardiovascular and respiratory diseases, diabetes, immunosuppression, etc. are wellknown associated with an increased susceptibility to pneumococcal disease and are further associated with higher mortality. There is limited data regarding IPD in adults in Latin America and particularly in Argentina, specially regarding IPD affecting people without evident co morbidities. The aim of this study was to analized the clinical presentation, mortality and serotypes involved in IPD in people without co morbidities (NC) and compare NC group with the people with co morbidities (C).


    Subanalisys of a prospective, multicenter and observational study of IPD in adults >18 yo in Argentina. S. pneumoniae strains obtained from normally sterile sites were evaluated. 


    From 25 centers in 11 provinces of Argentina (January 2000 to January 2002) 202 S. pneumoniae strains were isolated; 75 (37,13%) from people without evident comorbidities. Age: 64+DS 22; male sex 28,6%. Thirty patients (40%) were <65 yo. More frequent clinical presentation: pneumonia (72%) and meningitis (13.3%). Serotypes: 1, 3, 5, 14, 18 y 19A. All the strains were sensitive to penicillin. No people had previous pneumococcal vaccination. Hospital mortality 17.3%; 2/13 <65 yo; serotypes in people who died: 3, 14 and 19 A. There were no significant differences between NC and C group regarding clinical presentation of IPD (although NC group had more meningitis) and serotypes. Comparing between ages, people >65 yo had a non-significant tendency to mortality (6% vs 24%; p= 0.063).


    IPD may affect people of any ages and also those w/o any evident comorbidities. Age >65 yo seems a risk factor per se to IPD with or w/o associated comorbid diseases. Due to almost 40% of the people with IPD had no evident risk factors for it, population studies are needed in order to confirm these findings that could have implications for prevention with vaccines.

    Francisco Nacinovich, MD1, Marcelo Marin1, Pablo Bonvehi1, Jorge Héctor Gentile, MD1, Daniel Stamboulian1 and Invasive pneumococcal diseases study group, (1)Fundación Centro de Estudios Infectológicos, Ciudad Autónoma de Buenos Aires, Argentina


    F. Nacinovich, Pfizer: Scientific Advisor, Speaker honorarium

    M. Marin, None

    P. Bonvehi, Pfizer: Scientific Advisor, Speaker honorarium

    J. H. Gentile, None

    D. Stamboulian, Pfizer: Scientific Advisor, Speaker honorarium

    Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.